Clarification on consolidated results format for Sep 2025 quarter

Regulatory & Legal View source PDF Explain this filing

VAISHALI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.4%Reaction day

₹7.95

prior close

₹7.99

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-0.4% vs market

Pharmaceuticals peers, median of 157sector-0.5%-0.9% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.1

15m

+0.1

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.4-1.0-0.4-0.5-0.9

Next day

-0.3-1.8+1.5-1.2+0.9

+0.0+0.8-0.8+0.6-0.6

+1.9+1.8+0.1+1.0+0.9

+1.8+1.2+0.5+0.9+0.9

-0.6+0.7-1.4+0.1-0.7

+1.6-1.5+3.1-1.5+3.1

15d

-7.7-2.5-5.2-2.9-4.8

-15.2-7.2-8.0-5.0-10.2

-26.4-8.9-17.5-7.3-19.1

-1.9+5.5-7.4+0.4-2.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vaishali Pharma clarified to NSE that consolidated financial results for Sep 2025 quarter omit prior period comparative figures because the company acquired a 20.33% stake in Kesar Pharma on 10 Sep 2025, making it an associate under Ind AS 28. This is the first period requiring consolidation, so earlier figures are not comparable. The Sep 2024 and March 2025 columns in the balance sheet reflect standalone numbers only.

Likely market impact

Routine compliance clarification with no financial impact. Investors see consolidated numbers for the first time following the Kesar Pharma acquisition.